Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Social Deprivation Affects Survival in Waldenström Macroglobulinaemia: Experience in the United Kingdom

Jahanzaib Khwaja, Oliver M Tomkins, Nicole Japzon, Jindriska Lindsay, Charalampia Kyriakou, Shirley D'Sa

Blood (2024) 144 (Supplement 1): 7781.

https://doi.org/10.1182/blood-2024-207724

Published: 2024

Journal Articles

Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical

Ryan Low, Andrew Warden, Michelle Postek, Peter Denardis, Charalampia Kyriakou, Adam J. Olszewski, Marie José Kersten, Josephine M.I. Vos, Sheeba K. Thomas, Shirley D'Sa, Newton Guerin, Carl Harrington, Judith Trotman, Ibrahim Tohidi-Esfahani

Blood (2024) 144 (Supplement 1): 1654.

https://doi.org/10.1182/blood-2024-202820

Published: 2024

Journal Articles

Bing-Neel Syndrome - a Case Series of 46 Patients from the United Kingdom

Oliver M Tomkins, Jahanzaib Khwaja, Nicole Japzon, Shiwen Koay, Chandrashekar Hoskote, Charalampia Kyriakou, Jindriska Lindsay, Michael P Lunn, Shirley D'Sa

Blood (2024) 144 (Supplement 1): 3039.

https://doi.org/10.1182/blood-2024-206989

Published: 2024

Journal Articles

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Blood (2024) 144 (Supplement 1): 861.

https://doi.org/10.1182/blood-2024-200277

Published: 2024

Journal Articles

Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)

Blood (2024) 144 (Supplement 1): 4358.

https://doi.org/10.1182/blood-2024-211588

Published: 2024

Journal Articles

Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis

Jahanzaib Khwaja, Sriram Ravichandran, Darren Foard, Ana Martinez-Naharro, Lucia Venneri, Marianna Fontana, Carol Whelan, Philip N Hawkins, Julian Gillmore, Helen J Lachmann, Shameem Mahmood, Shirley D'Sa, Ashutosh D. Wechalekar

Blood (2024) 144 (Supplement 1): 4684.

https://doi.org/10.1182/blood-2024-207522

Published: 2024

Journal Articles

Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study

Shirley D'Sa, Meletios A. Dimopoulos, Wojciech Jurczak, Paula Marlton, Stephen P. Mulligan, Bjorn E Wahlin, Magdalena Sobieraj-Teague, Andrew W. Roberts, Constantine S. Tam, Jorge J. Castillo, Heather Allewelt, Radha Prathikanti, Wai Y Chan, Tian Tian, Jingjing Schneider, Remus Vezan, Stephen S. Opat

Blood (2024) 144 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2024-199276

Published: 2024

Journal Articles

Focal Symptomatic Bone Involvement with Waldenström's Macroglobulinaemia and Non-IgM Lymphoplasmacytic Lymphoma

Oliver M Tomkins, Nicole Japzon, Jahanzaib Khwaja, Jindriska Lindsay, Charalampia Kyriakou, Shirley D'Sa

Blood (2024) 144 (Supplement 1): 3023.

https://doi.org/10.1182/blood-2024-209771

Published: 2024

Journal Articles

Feasibility of Advanced Remote Health Monitoring in Waldenstrom Macroglobulinemia: Integrating Wearable Technology and Digital Quality of Life Tracking

Kim Z Summers, Orlando Agrippa, Muna Yusuf, Shirley D'Sa

Blood (2024) 144 (Supplement 1): 2339.

https://doi.org/10.1182/blood-2024-211274

Published: 2024

Journal Articles

Challenges in PNH and CAD Management Revealed through Educational Interventions over Three Years

Sumera Ackbarali, Tariqa Ackbarali, Katie Kowalski, Shirley D'Sa, Carlos M de Castro, Satheesh Chonat, Catherine M. Broome

Blood (2024) 144 (Supplement 1): 5087.

https://doi.org/10.1182/blood-2024-211593

Published: 2024

Journal Articles

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study

Shirley D’Sa, Josephine M. I. Vos, Wilma Barcellini, Marek Wardęcki, Laurent Perrin, Graham Barker, Moshe Zilberstein, Michael Storek, Timothy Chow, Alexander Röth

Blood (2024) 143 (8): 713–720.

https://doi.org/10.1182/blood.2023022153

Published: 2024

Includes: Supplemental data

Journal Articles

Using a Quality Improvement Activity to Enhance the Knowledge, Competence and Confidence of Clinicians Managing Patients with Cold Agglutinin Disease

Alison Scott, Bernd Jilma, Morie A Gertz, Shirley D'Sa, Luke Boothman, Alex Noble, Kathy Day, Sadaf Kazi

Blood (2023) 142 (Supplement 1): 5066.

https://doi.org/10.1182/blood-2023-172507

Published: 2023

Journal Articles

Ethnic Diversity in Presentation of Waldenström Macroglobulinaemia and IgM Mgcs in the United Kingdom- a Real-World Data Analysis

Jahanzaib Khwaja, Nicole Japzon, Maria Gabriel, Charles Lilley, Charalampia Kyriakou, Ali Rismani, Shirley D'Sa

Blood (2023) 142 (Supplement 1): 1668.

https://doi.org/10.1182/blood-2023-186561

Published: 2023

Journal Articles

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Blood (2023) 142 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2023-179940

Published: 2023

Journal Articles

Classical Complement Inhibition By SAR445088 (BIVV020) in Adults with Cold Agglutinin Disease: Safety, Tolerability and Activity Results from the Open-Label, Non-Randomized, Single-Dose Phase 1b Study

Shirley D'Sa, Josephine M.I. Vos, Wilma Barcellini, Marek Wardęcki, Laurent Perrin, Graham Barker, Moshe Zilberstein, Michael Storek, Timothy Chow, Alexander Roeth

Blood (2023) 142 (Supplement 1): 1069.

https://doi.org/10.1182/blood-2023-177886

Published: 2023

Journal Articles

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Jaimal Kothari, Toby A. Eyre, Ali Rismani, Helen McCarthy, Angela Collins, David John Lewis, Suzanne O Arulogun, William Wilson, Laura Clifton-Hadley, Darren Edwards, Kushani Ediriwickrema, Rebecca Auer, Guy Pratt, Ruth M. de Tute, Roger G Owen, Shirley D'Sa

Blood (2022) 140 (Supplement 1): 3624–3626.

https://doi.org/10.1182/blood-2022-167158

Published: 2022

Journal Articles

Type 1 Cryoglobulinaemia Associated with Waldenström Macroglobulinemia, IgM MGUS or Non-Hodgkin Lymphoma

Jahanzaib Khwaja, Simon Salter, Aisha S Patel, Robert Baker, Rajeev Gupta, Ali Rismani, Charalampia Kyriakou, Ashutosh D. Wechalekar, Josephine M.I. Vos, Shirley D'Sa

Blood (2022) 140 (Supplement 1): 3653–3654.

https://doi.org/10.1182/blood-2022-160438

Published: 2022

Journal Articles

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Kushani Ediriwickrema, Neil K Rabin, Shirley D'Sa, Graham Jackson, Peter Hoskin, Eve Gallop-Evans, Patricia Diez, Catherine Parbutt, Andre Lopes, Sevasti Galani, Laura Clifton-Hadley, Darren Edwards, Husne Timur Tezver, Ruth M. de Tute, Andrew Bates, Roger G Owen

Blood (2022) 140 (Supplement 1): 12626–12627.

https://doi.org/10.1182/blood-2022-158528

Published: 2022

Journal Articles

Addressing Clinical Management Challenges in the Treatment of Rare, Non-Malignant Hematologic Disorders through Educational Interventions

Sumera Ackbarali, Tariqa Ackbarali, Katie Kowalski, Hans C. Lee, Vaishali Sanchorawala, Shirley D'Sa, Satheesh Chonat, Carlos M. de Castro

Blood (2022) 140 (Supplement 1): 13057–13058.

https://doi.org/10.1182/blood-2022-157219

Published: 2022

Journal Articles

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Blood (2022) 140 (Supplement 1): 2825–2827.

https://doi.org/10.1182/blood-2022-159562

Published: 2022

NARROW

Social Deprivation Affects Survival in Waldenström Macroglobulinaemia: Experience in the United Kingdom

Real World Treatment Outcomes in the First Line Management of Waldenström Macroglobulinemia from the Global Patient Derived Data Registry, Whimsical

Bing-Neel Syndrome - a Case Series of 46 Patients from the United Kingdom

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Expanded Genome-Wide Association Study (GWAS) Identifies Nine Novel Germline Risk Loci for Waldenström Macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL)

Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis

Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study

Focal Symptomatic Bone Involvement with Waldenström's Macroglobulinaemia and Non-IgM Lymphoplasmacytic Lymphoma

Feasibility of Advanced Remote Health Monitoring in Waldenstrom Macroglobulinemia: Integrating Wearable Technology and Digital Quality of Life Tracking

Challenges in PNH and CAD Management Revealed through Educational Interventions over Three Years

Safety, tolerability, and activity of the active C1s antibody riliprubart in cold agglutinin disease: a phase 1b study

Using a Quality Improvement Activity to Enhance the Knowledge, Competence and Confidence of Clinicians Managing Patients with Cold Agglutinin Disease

Ethnic Diversity in Presentation of Waldenström Macroglobulinaemia and IgM Mgcs in the United Kingdom- a Real-World Data Analysis

Modified Staging System for Waldenström Macroglobulinemia (MSS-WM): A Multi-Institutional Externally Validated Prognostic Model for Active/Symptomatic Waldenström Macroglobulinemia

Classical Complement Inhibition By SAR445088 (BIVV020) in Adults with Cold Agglutinin Disease: Safety, Tolerability and Activity Results from the Open-Label, Non-Randomized, Single-Dose Phase 1b Study

Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Type 1 Cryoglobulinaemia Associated with Waldenström Macroglobulinemia, IgM MGUS or Non-Hodgkin Lymphoma

Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032)

Addressing Clinical Management Challenges in the Treatment of Rare, Non-Malignant Hematologic Disorders through Educational Interventions

Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only